Thromb Haemost 1989; 62(03): 955-961
DOI: 10.1055/s-0038-1651035
Original Article
Schattauer GmbH Stuttgart

Differential Ability of Agonists to Express Distinct Pools of Fibrinogen (Gpllb/llla) Receptors which Can Mediate the Aggregation of Human Platelets

Autoren

  • Ian S Watts

    The Department of Cardiovascular Pharmacology, Glaxo Group Research Ltd, Ware, Hertfordshire, UK
  • Rebecca J Keery

    The Department of Cardiovascular Pharmacology, Glaxo Group Research Ltd, Ware, Hertfordshire, UK
  • Philip Lumley

    The Department of Cardiovascular Pharmacology, Glaxo Group Research Ltd, Ware, Hertfordshire, UK
Weitere Informationen

Publikationsverlauf

Received: 25. Januar 1989

Accepted after revision 29. Mai 1989

Publikationsdatum:
30. Juni 2018 (online)

Summary

We have investigated the effect of two procedures that modify human platelet surface membrane glycoprotein (Gp) IIb and IIIa complexes upon whole blood platelet aggregation to a range of agonists. (A) Irreversible disruption of complexes by temporary (30 min) Ca2+-deprivation with EGTA at 37° C. (B) Binding of a monoclonal antibody M148 to the complex. EGTA exposure abolished aggregation to ADP, adrenaline and PAF. In contrast, full aggregation curves to collagen and U-46619 could still be established. EGTA exposure reduced M148 binding to platelets by 80%. Excess M148 abolished aggregation to ADP, PAF, collagen and U-46619. However, upon removal of unbound antibody from platelets full aggregation curves to collagen and U-46619 but not to ADP and PAF could be re-established. Thus human platelet aggregation to ADP, PAF and adrenaline appears absolutely dependent upon surface membrane GpIIb/IIIa complexes. In contrast, collagen and U-46619 cause expression of an additional distinct pool of Gp complexes inaccessible to EGTA and M148 in unstimulated platelets which is intimately involved in aggregation to these agonists.